Prognostic significance of the treatment-free interval in patients with recurrent endometrial cancer

Shimamoto, Kumi; Saito, Toshiaki; Okadome, Masao; Shimokawa, Mototsugu

doi:10.1016/j.ejogrb.2014.01.002

Cited by 8 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies reported that 70% to 86% of incidences of recurrence are detected within 3 years after primary treatment and that the 3-year OSr is 17% to 35%, [ 6 , 10 , 17 ] findings similar to our results. However, only a handful of studies addressed the prognostic factors associated with OSr in these patients and as yet there is no consensus.…”

Section: Discussionsupporting

confidence: 92%

“…Table 5 summarizes the published studies reporting the prognostic factors for OSr in recurrent EC patients. Commonly suggested prognostic factors for OSr include TTR, [ 6 , 8 , 15 – 22 ] number of recurrent lesions, [ 21 , 23 , 24 ] site of recurrence, [ 5 , 6 , 9 , 16 , 22 , 25 , 26 ] CA-125 level at recurrence, [ 24 , 27 ] histology, [ 20 ] grade, [ 9 , 10 , 28 ] initial stage, [ 10 ] symptomatic recurrence, [ 10 , 17 , 18 , 29 ] performance status, [ 8 ] and use of pelvic radiation after initial surgery. [ 5 , 6 , 8 , 22 , 23 ] To build a reliable model, we tested all aforementioned variables for inclusion.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Stratification of risk groups according to survival after recurrence in endometrial cancer patients

Shim

Kim

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Stratification of risk groups according to survival after recurrence in endometrial cancer patients

Shim

Kim

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

“…The risk of PC failure for REC patients receiving radiotherapy and chemotherapy, DFI less than 12 months after primary surgery, and other treatment plans increased. Similar to ours, the team of Shimamoto pointed out that the effect of chemotherapy on the therapeutic effect of REC patients may be determined by DFI, and patients with DFI ≥12 months have better therapeutic response [ 23 ]. For patients who received radiotherapy and chemotherapy after primary surgery, we speculated that the body might already have certain drug resistance, which more or less affected the effectiveness of the treatment mode after relapse.…”

Section: Discussionmentioning

confidence: 86%

“…The DFI is the disease-free interval and is an important prognostic indicator for patients with stage I–IV REC. DFI less than 12 months often symbolizes short-term recurrence, which we speculate may be related to poor treatment [ 22 , 23 ]. In the study of Murakawa et al [ 24 ], the treatment mode is obviously related to OS of tumor patients, which is different from our research results.…”

Section: Discussionmentioning

confidence: 99%

Analysis of Prognostic Factors and Treatment Modes of Patients with Recurrent Endometrial Carcinoma

Yang

2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. Recurrence of endometrial cancer after initial treatment can be complex and difficult to treat. The current main treatment modalities for patients with recurrent endometrial cancer (REC) include chemotherapy, radiotherapy, and surgery, which vary according to the individual patient. However, REC is often associated with a poor prognosis, and it is therefore important to investigate the risk factors affecting REC prognosis and to explore appropriate treatment modalities to improve the prognosis and treatment strategies for patients with REC. Methods. Totally, 100 patients with REC admitted to our hospital from January 2013 to January 2018 were chosen to be research objects. Their pathological data were analyzed, including age, disease-free interval (DFI), recurrence site, and treatment plan after relapse (definitive local therapy (DLT) and palliative chemotherapy (PC)). According to these parameters, univariate and multivariate factors affecting the prognosis of REC patients and the curative effect of PC were analyzed, and the 3-year overall survival (OS) curve and progression-free survival (PFS) curve were drawn. Results. After 3 years of follow-up, 30 patients had a poor prognosis and 70 had a good prognosis, according to which a single multifactorial analysis was performed for different prognoses, where the results of the single-factor analysis showed significant differences between patients with different prognoses in terms of pathomorphology, pathological grading, TFI, and treatment modality after relapse. Further multifactorial analysis showed that TFI and treatment modality after recurrence were independent factors affecting poor prognosis in REC patients. The 3-year OS and 3-year PFS of REC patients were 74.00% and 70.00%, respectively. Patients whose DFI was less than 12 months or treated with PC after relapse were notably associated with lower levels of 3-year OS and 3-year PFS. In addition, radiotherapy and chemotherapy, DFI, and chemotherapy plan after primary surgery were independent risk factors that affected the PC efficacy of REC patients. Conclusion. DFI and treatment mode after relapse are independent factors affecting the prognosis of REC patients. DLT can obviously improve the prognosis of REC patients. For patients who can only choose PC, chemoradiotherapy and DFI after primary surgery are helpful to predict the chemotherapy effect, and the combination of paclitaxel and platinum drugs should be the first choice for chemotherapy.

show abstract

“…Subsequently, 17 articles were excluded from the study for reasons that are presented in detail in the research chart ( Figure 1 ). In four of the excluded articles, only the locations of the distant lymph nodes were detailed and the distribution of those were: cervical and supraclavicular nodes, 5 cases ( 13 ); inguinal nodes, 5 cases ( 13 , 14 , 15 ); cervical nodes, 5 cases ( 14 ); supraclavicular nodes, 2 cases ( 16 ); subclavian nodes, 2 cases ( 14 ); and axillary lymph nodes, 1 case ( 16 ). Therefore, only the frequency of involved nodes for these cases from the four articles was included in the analysis.…”

Section: Methodsmentioning

confidence: 99%

Evaluation of peripheral nodal recurrence in patients with endometrial cancer

Kılıç¹,

Cömert²,

Akar³

et al. 2022

J Turkish German Gynecol Assoc

View full text Add to dashboard Cite

Objective: To evaluate the clinico-pathological patient features, prognostic factors, treatment options and outcomes of peripheral nodal recurrence (PNR) of endometrial cancer (EC). Material and Methods: The data of nine patients with PNR of EC from two institutions were reviewed. The electronic literature was reviewed from 1972 to May 2018 to identify articles about PNR in EC. Finally, 42 cases were evaluated. Results: Nineteen (45.2%) patients were initially diagnosed with either stage I or II disease, whereas 20 (47.7%) patients had stage III or IV disease while the stages were not reported in three (7.1%). PNR developed as the first recurrence in 40 (95.2%) patients and as the second recurrence in 2 (4.8%) patients. Isolated PNR appeared in 35 (83.3%). Seven (16.7%) had PNR coexisting with multiple other sites of tumoral involvement. In the entire cohort, the 5-year and 10-year post-recurrence survival (PRS) were both 78%. Only the presence of distant hematogenous metastasis concurrent with PNR was significantly related to poor PRS (p=0.005). Among patients with isolated PNR, those who had surgery had 30% greater 5-year PRS than those treated without surgery, but this difference was not significant (80% vs 50%; p>0.05). Conclusion: A concurrent distant hematogenous metastasis was the only factor related to poor survival. A wide range of therapies exists for PNR but none of the therapies appear to be more advantageous than another. However, surgery as a component of treatment can render a survival advantage for patients who have isolated PNR.

show abstract

Prognostic significance of the treatment-free interval in patients with recurrent endometrial cancer

Cited by 8 publications

References 17 publications

Stratification of risk groups according to survival after recurrence in endometrial cancer patients

Stratification of risk groups according to survival after recurrence in endometrial cancer patients

Analysis of Prognostic Factors and Treatment Modes of Patients with Recurrent Endometrial Carcinoma

Evaluation of peripheral nodal recurrence in patients with endometrial cancer

Contact Info

Product

Resources

About